Immix Biopharma Inc. logo

Immix Biopharma Inc.

IMMX | NASDAQ
Chart Builder DCF Calculator
$7.20
-$0.77 (-9.66%)
At close: Nov 4, 2026, 4:00 PM ET
$7.27
+$0.07 (+0.97%)
After-hours: Nov 5, 2026, 4:27 PM ET
Fiscal Year
Period Ending
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Cash & Equivalents
93.93M 17.68M 17.51M 13.44M 17.64M 391.09K
Short-Term Investments
6.48M n/a n/a n/a n/a n/a
Long-Term Investments
n/a n/a n/a n/a n/a n/a
Other Long-Term Assets
114.05K 20.42K 87.23K 6.72K n/a n/a
Receivables
n/a 1.97M 1.17M 255.71K 25.72K 127.44K
Inventory
n/a n/a n/a n/a n/a n/a
Other Current Assets
150.72K 32.27K 44.58K 78.07K n/a n/a
Total Current Assets
101.24M 20.2M 19.79M 14.9M 18.19M 532.24K
Property-Plant & Equipment
3.49M 2.73M 50.18K 3.56K 5.7K 7.36K
Goodwill & Intangibles
n/a n/a n/a n/a n/a n/a
Total Long-Term Assets
3.6M 2.75M 137.41K 10.28K 5.7K 7.36K
Total Assets
104.84M 22.95M 19.93M 14.91M 18.19M 539.6K
Account Payables
5.44M 5.39M 1.43M 143.07K 142.94K 252.34K
Deferred Revenue
n/a n/a n/a n/a n/a 342.84K
Short-Term Debt
n/a n/a n/a n/a 50K 4.1M
Other Current Liabilities
n/a 658.16K n/a n/a n/a 232.16K
Total Current Liabilities
10.11M 8.69M 3.72M 1.27M 202.04K 5.27M
Long-Term Debt
n/a n/a n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a 475K n/a n/a
Total Long-Term Liabilities
933.63K 1.01M n/a 475K n/a n/a
Total Liabilities
11.04M 9.7M 3.72M 1.75M 202.04K 5.27M
Total Debt
1.07M 1.07M n/a n/a 50K 4.1M
Book Value
93.8M 13.25M 16.2M 13.16M 17.99M -4.73M
Book Value Per Share
2.85 0.47 0.93 0.95 4.90 -0.61
Common Stock
5.3K 2.76K 2K 1.4K 1.32K 338
Retained Earnings
-104.46M -75.02M -53.41M -37.99M -29.76M -5.37M
Comprehensive Income
60.16K -1.06K 134.67K 87.02K 125.41K 131.86K
Shareholders Equity
93.8M 13.25M 16.41M 13.16M 17.99M -4.73M
Total Investments
6.48M n/a n/a n/a n/a n/a

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.